Design, synthesis, and biological activity of novel 5-((arylfuran/1 H -pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl) thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41

Journal of Medicinal Chemistry

Volumn 54, Issue 2, 2011, Pages 572-579

  Jiang, Shibo ^a   Tala, Srinivasa R ^b   Lu, Hong ^a   Abo Dya, Nader E ^b,c   Avan, Ilker ^b,d   Gyanda, Kapil ^b   Lu, Lu ^a   Katritzky, Alan R ^b   Debnath, Asim K ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b University of Florida ^*  (United States)

^c Zagazig University   (Egypt)

^d ANADOLU UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(ARYLFURAN/1H PYRROL 2 YL)METHYLENE] 2 THIOXO 3 [3 (TRIFLUOROMETHYL)PHENYL]THIAZOLIDIN 4 ONE; CARBOXYL GROUP; CARBOXYLIC ACID; FURAN; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; ION; LYSINE; PYRROLE; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CELL FUSION; CONTROLLED STUDY; DNA HELIX; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHOBICITY; LABORATORY; LABORATORY INFECTION; MOLECULAR DOCKING;

CELL LINE; DRUG DESIGN; FURANS; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINES; VIRUS INTERNALIZATION;

EID: 78751657690     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101014v     Document Type: Article

References (39)

1. Johnson, V. A.; Brun-Vézinet, F.; Clotet, B.; Conway, B.; DAquila, R. T.; Demeter, L. M.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J. M.; Telenti, A.; Richman, D. D. Drug resistance mutations in HIV-1 Top. HIV Med. 2003, 11, 215-221
2. Richman, D. D.; Morton, S. C.; Wrin, T.; Hellmann, N.; Berry, S.; Shapiro, M. F.; Bozzette, S. A. The prevalence of antiretroviral drug resistance in the United States AIDS 2004, 18, 1393-1401
3. Carr, A.; Cooper, D. A. Adverse effects of antiretroviral therapy Lancet 2000, 356, 1423-1430
4. Eckert, D. M.; Kim, P. S. Mechanisms of viral membrane fusion and its inhibition Annu. Rev. Biochem. 2001, 70, 777-810
5. Moore, J. P.; Doms, R. W. The entry of entry inhibitors: a fusion of science and medicine Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10598-10602
6. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds Curr. Pharm. Des. 2007, 13, 143-162
7. Lu, M.; Blacklow, S. C.; Kim, P. S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein Nat. Struct. Biol. 1995, 2, 1075-1082
8. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein Cell 1997, 89, 263-273
9. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41 Nature 1997, 387, 426-428
10. Tan, K.; Liu, J.; Wang, J.-H.; Shen, S.; Liu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41 Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 12303-12308
11. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15613-15617
12. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 2004, 48, 4349-4359
13. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q.-Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A. K. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3- phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors J. Med. Chem. 2009, 52, 7631-7639
14. Debnath, A. K.; Radigan, L.; Jiang, S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodecifiency virus type 1 J. Med. Chem. 1999, 42, 3203-3209
15. He, Y.; Liu, S.; Li, J.; Lu, H.; Qi, Z.; Liu, Z.; Debnath, A. K.; Jiang, S. Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition J. Virol. 2008, 82, 11129-11139
16. 574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry J. Biol. Chem. 2007, 282, 25631-25639
17. Jiang, S.; Debnath, A. K. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity Biochem. Biophys. Res. Commun. 2000, 270, 153-157
18. Wang, H.; Qi, Z.; Guo, A.; Mao, Q.; Lu, H.; An, X.; Xia, C.; Li, X.; Debnath, A. K.; Wu, S.; Liu, S.; Jiang, S. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking the fusion-active gp41 core formation Antimicrob. Agents Chemother. 2009, 53, 4987-4998
19. Ikemoto, T.; Nishiguchi, A.; Mitsudera, H.; Wakimasu, M.; Tomimatsu, K. Convenient efficient synthesis of TAK-779, a nonpeptide CCR5 antagonist: development of preparation of various ammonium salts using trialkylphosphite and N -halogenosuccinimide Tetrahedron 2001, 57, 1525-1529
20. Jiang, S.; Lin, K.; Lu, M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein J. Virol. 1998, 72, 10213-10217
21. Liu, S.; Lu, H.; Xu, Y.; Wu, S.; Jiang, S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 J. Biol. Chem. 2005, 280, 11259-11273
22. Wittenberger, S. J.; Donner, B. G. Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles J. Org. Chem. 1993, 58, 4139-4141
23. Brown, F. C.; Bradsher, C. K.; Morgan, E. C.; Tetenbaum, M.; Wilder, P. Some 3-substituted rhodanines J. Am. Chem. Soc. 1956, 78, 384-388
24. Shrestha, S.; Bhattarai, B. R.; Lee, K.-H.; Cho, H. Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs Bioorg. Med. Chem. 2007, 15, 6535-6548
25. Bray, B. L.; Muchowski, J. M. α-(Dialkylamino)-α- pyrrolylacetonitriles. A potpourri of useful synthetic transformations Can. J. Chem. 1990, 68, 1305-1308
26. Kurach, P.; Luliński, S.; Serwatowski, J. One-pot generation of lithium (lithiophenyl)trialkoxyborates from substituted dihalobenzenes (HAL = Br, I) and their derivatization with electrophiles Eur. J. Org. Chem. 2008, 3171-3178
27. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds Chem. Rev. 1995, 95, 2457-2483
28. Zhang, R.; Chan, D.; Jessica, S.; Iskander, G.; Black, D. S.; Kumar, N. Synthesis of new aryl substituted 5-alkylidenefuran-2(5 H)-ones ARKIVOC 2009, v, 102-115
29. 2+ release from sarcoplasmic reticulum of mouse skeletal muscle Bioorg. Med. Chem. 2003, 11, 663-673
30. Bumagin, N. A.; Bykov, V. V. Ligandless palladium catalyzed reactions of arylboronic acids and sodium tetraphenylborate with aryl halides in aqueous media Tetrahedron 1997, 53, 14437-14450
31. Rajamaki, S.; Innitzer, A.; Falciani, C.; Tintori, C.; Christ, F.; Witvrouw, M.; Debyser, Z.; Massa, S.; Botta, M. Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 3615-3618
32. Wang, G.-W.; Cheng, B. Solvent-free and aqueous Knoevenagel condensation of aromatic ketones with malononitrile ARKIVOC 2004, ix, 4-8
33. Gupta, M.; Wakhloo, P. B. Tetrabutylammoniumbromide mediated Knoevenagel condensation in water: synthesis of cinnamic acids ARKIVOC 2007, i, 94-98
34. Singh, S. P.; Parmar, S. S.; Raman, K.; Stenberg, V. I. Chemistry and biological activity of thiazolidinones Chem. Rev. 1981, 81, 175-203
35. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. Identification of N -phenyl- N ′-(2,2,6,6- tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4 Virology 2005, 339, 213-225
36. Chou, T. C.; Hayball, M. P. CalcuSyn: Windows Software for Dose Effect Analysis; BIOSOFT: Ferguson, MO, 1991.
37. Jiang, S.; Lin, K.; Zhang, L.; Debnath, A. K. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody J. Virol. Methods 1999, 80, 85-96
38. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein Cell 1997, 89, 263-273
39. Shu, W.; Liu, J.; Ji, H.; Radigan, L.; Jiang, S.; Lu, M. Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides Biochemistry 2000, 39, 1634-1642